HolmesC.J.Biocompatibility of peritoneal dialysis solutions.Perit Dial Int1993; 13: 88–94.
2.
de FijterC.W.H., OeP.L., DonkerA.J.M., VerhoefJ., VerbrughH.A.Compatibility of peritoneal dialysis fluids containing alternative osmotic agents with cells present in the peritoneal cavity.Perit Dial Int1994; 14(Suppl 2): S33–8.
3.
TopleyN., ColesG.A., WilliamsJ.D.Biocompatibility studies on peritonealcells.Perit Diallnt1994; 14(Suppl 3): S21–8.
4.
BrulezH.F.H., HeeziusECJM, de FijterC.W.J., OeL.P., VerhoefJ., VerbrughH.A.In vitro compatibility of a 1.1% amino acid containing peritoneal dialysis fluid with phagocyte function. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1994; 10: 241–4.
5.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
6.
LiberekT., TopleyN., JörresA., ColesG.A., GahlG.M., WilliamsJ.D.Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration.J Am Soc Nephrol1993; 3: 1508–15.
7.
BreborowiczA., MartisL., OreopoulosD.G.In vitro influence of lactate on function of peritoneal fibroblasts. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1994; 10: 225–9.
8.
BreborowiczA., WitowskiJ., KnapowskiJ., SerkesK.D., MartisL., OreopoulosD.G.In vitro study of the mechanism of potassium transport into human mesothelial cells. 1: Effect of hyperosmolality.Perit Dial Int1993; 13: 201–7.
9.
AmeyiyamaM., MoeO.W., AlpernR.J.Chronic hyperosmolality increases Na/H antiporter activity in OKP cells.J Am Soc Nephrol1994; 5: 246.
10.
RandallJ., KojimaR., GullansS.Identification of differ entially expressed genes during adaptation to hyper osmolar stress.J Am Soc Nephrol1994; 5: 319.
11.
van BronswijkH., VerbrughH.A., HeeziusHCJM, van der MeulenJ., OeP.L., VerhoetJ.Dialysis fluids and local host resistance in patients on continuous ambulatory peritoneal dialysis.Eur J Clin Microbiol Infect Dis1988; 7: 368–73.
12.
TopleyN., MackenzieR., PetersenM.M.In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid.Nephrol Dial Transplant1991; 6: 574–81.
13.
ZhouF.Q., ManahanF.J., WuA.W.Effects of hypertonic peritoneal dialysis solutions on neutrophil superoxide production.Artif Organs1990; 14: 410–12.
14.
JörresA., GahlG.M., TopleyN.In vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions.Nephrol Dial Transplant1994; 9: 785–90.
15.
JörresA., GahlG.M., TopleyN., FreiU., Passlick-DeetjenJ.Limited recovery of stimulated cytokine release from leukocytes following exposure to CAPD fluids.Nephrol Dial Transplant1994; 9: 1021–2.
16.
BreborowiczA., RodelaH., OreopoulosD.G.Toxicity of osmotic solutes on human mesothelial cells in vitro.Kidney Int1992; 41: 1280–5.
17.
KumanoK., Schiller-MoranB., HjelleJ.T., MoranJ.E.Effects of high glucose levels on cell proliferation and TGF -β expression in cultured rat mesothelial cells.J Am Soc Nephrol1993; 4: 410.
18.
BorderW.A., RuoslahtiE.Transforming growth factor β in disease: the dark side of tissue repair.J Clin Invest1992; 90: 1–7.
19.
van BronswijkH., VerbrughH.A., BosH.J.Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro.Perit Dial Int1989; 9: 197–202.
20.
SchenkV., KieferJ., HubelE.In vitro effects of amino acid based versus glucose based continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function.Nephron1994; 68: 338–46.
21.
BreborowiczA., BalaskasE., OreopoulosG.D., MartisL., SerkesK., OreopoulosD.G.In vitro study of the effect of osmotic solutes on the interactions between cells from the peritoneum and peritoneal cavity.Perit Dial Int1994; 14: 149–54.
22.
BreborowiczA., WitowskiJ., KnapowskiJ., OreopoulosG.D., BalaskasE.V., OreopoulosD.G.In vitro cytotoxicity of amino acids and their glycyl-dipeptide form to human peritoneal mesothelial cells.Perit Dial Int1994; 14: 182–4.
23.
BreborowiczA., BalaskasE., WitowskiJ., DiamandisE., GressL., OreopoulosD.G.In vitro study of the synthesis of tumour necrosis factor (TNF) in the presence of osmotic solutes and its effect on function of human mesothelial cells (HMC).Nephrol Dial Transplant1993; 8: 1018.
24.
LiberekT., TopleyN., MistryC.D.Cell function and viability in glucose polymer peritoneal dialysis fluids.Perit Dial Int1993; 13: 104–11.
25.
De FijterC.W.H., VerbrughH.A., OeL.P.Biocompatibility of a glucose-polymer-containing dialysis fluid.Am J Kidney Dis1993; 21: 411–18.
26.
Di PaoloN., GarosiG., BiagoliM.Effects of dialysis fluids on cultured mesothelial cells.Perit Dial Int1994; 14(Suppl 3): S12–15.
27.
De FijterC.W.H., VerbrughH.A., PetersE.D.J.Invivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD.Clin Nephrol1993; 39: 75–80.
28.
De FijterC.W.H., VerbrughH.A., OeP.L.The effect of glycerol-containing peritoneal dialysis fluid on peritoneal macrophage function in vivo. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1991; 7: 154–7.
ManiarS., LaouariD., DechauxM.In vivo unaltered muscle protein synthesis in experimental chronic metabolic acidosis.Kidney Int1994; 46: 1705–12.
32.
MistryC.D., GokalR., PeersE, and the MIDAS Study Group. A randomized multicentre clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutes in CAPD.Kidney Int1994; 46: 496–503.
33.
Nilsson-ThorellC.B., MuscaluN., AndrenA.H.G., KjellstrandP.T.T., WieslanderA.P.Heat sterilization of fluid for peritoneal dialysis gives rise to aldehydes.Perit Dial Int1993; 13: 208–13.
34.
KorbetS.M., MakitaZ., FiranekC.A., VlassaraH.Advanced glycosylation end products in continuous ambulatory peritoneal dialysis patients.Am J Kidney Dis1993; 22: 588–91.
35.
FriedlanderM.A., WuY.C., MonnierV.M.Kinetics of formation of advanced glycosylation end products (AGEs) in peritoneal dialysis.J Am Soc Nephrol1994; 5: 447.
36.
MahioutA., ErlerdingG., KrautizigS., BrunkhorstR.Production of advanced glycosylation end products (AGE) in the peritoneum of CAPD patients.J Am Soc Nephrol1994; 5: 464.
37.
KumanoK., ManalaysayM.T., HyodoT., SakaiT., NakamuraK.Effects of advanced glycation end product of albumin on cell proliferation and protein synthesis in rat peritoneal mesothelial cells.J Am Soc Nephrol1994; 5: 460.
38.
YamadaK., MiyaharaY., HamaguchiK.Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure.Clin Nephrol1994; 42: 354–61.
39.
DobbieJ.W.Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis.Perit Dial Int1992; 12: 14–27.
